首個KRAS抑制劑-索托拉西布或將面臨下市！ – medfind.link
这是继武田的莫博替尼之后， 国庆假期期间又一项因为II期研究被加速批准适应症然后因为III期确证性研究失败而面临退市风险的药物！
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
文章相關商品
系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。
常見問題
Which products are related to this article?
The system matched these relevant products from the article content: 盧修斯 索托拉西布 Sotorasib 在線購買.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
